Standard CXL better at stabilizing progressive keratoconus

Article

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus

Benzalkonium chloride-assisted (BAC) transepithelial collagen crosslinking (CXL) with 0.5% proparacaine drops is less effective than standard CXL in patients with progressive keratoconus, claims a study in the Journal of Cataract and Refractive Surgery.

The study, headed by Dr Carina Koppen, Department of Ophthalmology, Antwerp University Hospital, Belgium, enrolled 53 eyes of 38 keratoconus patients. The Placido disk device was used to measure sphere, cylinder, as well as maximum keratometry (K max) simulated K values and refractive power values.

Standard CXL was preceded by administration of proparacaine drops 0.5% preserved with BAC 0.005% every five minutes during a thirty minute time period. Results were compared before CXL and post-CXL at 6, 12 and 18 months.

Only corrected distance visual acuity demonstrated a statistically significant improvement at six and twelve months postoperatively. Standard CXL was significantly more effective in stabilizing progressive keratoconus.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.